The use of antibodies to coagulation factors for anticoagulant therapy

Current Medicinal Chemistry
M Jacquemin, J M Saint-Remy

Abstract

Current treatments for preventing thrombotic diseases are associated with a significant risk of bleeding. Improved anticoagulant agents are therefore still required. The specificity and pharmacokinetics properties of monoclonal antibodies to coagulation factors allow novel anticoagulation approaches. Treatment with human antibodies or humanized mouse monoclonal antibodies should avoid unacceptable side effects due to immune response to the drug. Such antibodies were developed against three coagulation factor: Tissue factor (TF), Factor IX (FIX) and Factor VIII (FVIII). A fully humanized antibody was successfully derived from a mouse monoclonal antibodies to TF. In vivo studies with monoclonal antibodies to TF demonstrated efficient antithrombotic activity. Anti-TF antibodies may also prove useful in cardiovascular disorders and cancer, given the role of TF in these diseases. Mouse and human monoclonal antibodies to FIX were also efficient to prevent thrombosis in animal models of venous and arterial thrombosis and in stroke. A humanized anti-FIX antibody was tested in phase I study in healthy volunteers. The pharmacokinetics of the antibody were determined by the rapid formation of stable complexes with newly synthesised FIX. H...Continue Reading

Citations

Apr 16, 2010·Arteriosclerosis, Thrombosis, and Vascular Biology·Colin A KretzPeter L Gross

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Haemophilia : the Official Journal of the World Federation of Hemophilia
Sébastien Lacroix-DesmazesMichel D Kazatchkine
Molecular Therapy : the Journal of the American Society of Gene Therapy
Federico MingozziKatherine A High
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
Sébastien Lacroix-DesmazesSrini V Kaveri
Haemophilia : the Official Journal of the World Federation of Hemophilia
K Peerlinck, M Jacquemin
© 2021 Meta ULC. All rights reserved